SpectraScience, Inc. (SpectraScience) has developed a minimally invasive technology known as WavSTAT Optical Biopsy System (WavSTAT System), which optically scans tissue in real time to distinguish between normal, pre-cancerous or cancerous cells without the need to remove the subject cell tissue from the body to make such determinations. SpectraScience has received approval from the United States Food and Drug Administration (FDA) to market the WavSTAT System. The Company has also developed an additional application for the detection of pre-cancerous and cancerous tissue in the esophagus, as well as has expanded its product offerings to cervical cancer and pre-cancer detection through the acquisition of Luma Imaging Corporation (LUMA). LUMA has developed and received approval from the FDA for an optical, non-invasive diagnostic imaging system to detect cervical cancer precursors.